Drug DevelopmentSulfateq BV has identified huge potential for its SUL-compounds to support drug development for important medical needs worldwide like Acute Kidney Injury, COPD and obesity/diabetes II.
Acute Kidney Injury Drug Development
Cardiac surgery with cardiopulmonary bypass is associated with a significant risk of acute kidney injury (AKI). The incidence of postoperative acute kidney injury (AKI) in patients undergoing cardiac surgery ranges from 7.7% to 28.1% in different studies and can therefore be considered a major health risk and medical need. The protection of major organs like the kidneys is highly needed during (long-lasting) major surgery. There is currently no therapy available for kidney protection, or organ protection in general, during major surgery.
Sulfateq BV has conducted very succeful first animal studies using its SUL-compounds, focussing on the protection against hypothermia-induced kidney damage during invasive (heart) surgery. It will increase post-operative survival rate and decrease the risk of Acute Kidney Injury. We therefore see huge potential to address this major organ related medical need with SUL-compounds based drug development.
COPD Drug Development
Chronic Obstructive Pulmonary Disease (COPD) is a major public health problem. According to the WHO COPD is an under-diagnosed, life threatening lung disease that may progressively lead to death.
Sulfateq BV has conducted very succeful first animal studies using its SUL-compounds, focussing on countarcting airway constriction and immune activation. We therefore see huge potential to address this major COPD related medical need with SUL-compounds based drug development.
Other potential drug development
The chemistry of hibernation could also be benificial for the treatment of Diabetes II / Obesity. Though Sulfateq BV its current focus is on COPD and AKI, the results of preliminary studies have been very hopeful for further investigation.